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Abstract: Tumor tissue biopsy is often limited for non-small cell lung cancer (NSCLC) patients and
alternative sources of tumoral information are desirable to determine molecular alterations such as
anaplastic lymphoma kinase (ALK) rearrangements. Circulating tumor cells (CTCs) are an appealing
component of liquid biopsies, which can be sampled serially over the course of treatment. In this study,
we enrolled a cohort of ALK-positive (n = 8) and ALK-negative (n = 12) NSCLC patients, enriched for
CTCs using spiral microfluidic technology and performed DNA fluorescent in situ hybridization
(FISH) for ALK. CTCs were identified in 12/20 NSCLC patients ranging from 1 to 26 CTCs/7.5 mL
blood. Our study revealed that 3D imaging of CTCs for ALK translocations captured a well-defined
separation of 3′ and 5′ signals indicative of ALK translocations and overlapping 3′/5′ signal was
easily resolved by imaging through the nuclear volume. This study provides proof-of-principle for
the use of 3D DNA FISH in the determination of CTC ALK translocations in NSCLC.
Keywords: circulating tumor cells; anaplastic lymphoma kinase; non-small cell lung cancer
1. Introduction
Lung cancers are the leading cause of cancer-related deaths in the world with 85% of all cases
being non-small cell lung cancer (NSCLC). Patients are often diagnosed at an advanced stage,
where the immediate prognosis is often poor, resulting in poor five-year survival rates of 23% [1].
A subset of patients, approximately 3–7% of NSCLC, present with anaplastic lymphoma kinase (ALK)
rearrangements. These are usually associated with never smokers representing a younger patient
age group with signer or acinar histology. In tumor biopsy, ALK is determined to be positive when
>50% of counted nuclei (typically out of 50) are positive. If <10% are positive, it is considered negative
and equivocal when this ranges between 10% and 50% positivity where an additional 50 nuclei are
analyzed and scored out of 100 total nuclei to determine the ALK score [2,3]. These patients are eligible
for ALK-targeted therapies such as crizotinib (tyrosine kinase inhibitor). Crizotinib was originally
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developed as an inhibitor of mesenchymal–epithelial transition factor (c-MET) and found to be a
potent inhibitor of ALK [4]. Patients treated with crizotinib have better response rates and longer
progression-free survival compared with standard chemotherapy, however, patients often undergo
relapse due to the emergence of resistance mechanisms [5]. To better understand the emergence of
treatment resistance, it is crucial to be able to sample the tumor over the course of therapy [6]. In the
case of lung cancer, this can be invasive and oftentimes challenging due to the location of the tumor.
Therefore, minimally invasive means of sampling and capturing the tumor activities in real time are
needed [7–9].
Liquid biopsies have emerged as an alternative source of tumor material that can be minimally
invasively and serially sampled over the course of therapy in NSCLC [10,11]. In recent years, EML4-ALK
rearrangements have been reported to be found in circulating tumor cells (CTCs) [12–17]. Fluorescent
in situ hybridization (FISH) allows for the visualization of the organization and positioning of
chromosomes and subchromosomal regions. 3D FISH provides spatial organization of the chromosomes
within the nuclei, where gene-to-gene distances can be assessed with more precision than the classical
2D FISH [18]. However, 3D FISH experimentation has the additional steps involved such as region of
interest selection, cell segmentation, detection of signal within the nuclear space, and localization of
genes [19,20]. In this proof-of-principle study, we sought to investigate the role of ALK translocations
from a cohort of ALK-positive and ALK-negative NSCLC patients.
2. Results
For this study, a cohort of ALK-positive (n = 8) and ALK-negative (n = 12) NSCLC patients
were recruited. ALK for tumor tissue was confirmed by ALK protein staining (ALK CDx assay)
using the Ventana ALK (C5F3) companion diagnostic test (Roche Diagnostics, Indianapolis, IN, USA).
All ALK-positive NSCLC patients received a form of tyrosine kinase inhibitor (crizotinib, ceritinib,
or alectinib). CTCs were detected in n = 13/20 patient samples (5/8 ALK-positive cases and 7/12
ALK-negative cases) ranging from 1 to 26 CTCs/7.5 mL blood (Figure 1). No CTC clusters were
found in the 12 CTC-positive samples. Prior to staining the CTC-positive slides, control tissue was
assessed to determine the staining patterns of the Vysis LSI ALK break-apart probes (Abbott, Chicago,
IL, USA) (Figure 2). The Vysis LSI ALK break-apart probes showed clear ALK translocations in the
ALK-positive tumor slides (Figure 2A,B) and the non-ALK-translocated tumor tissue showed no signal
separation (Figure 2C,D). The CTC-positive cases were further analyzed using 3D ALK-DNA FISH
(Figure 3A,C) individual images whilst imaging through the nuclear volume of CTCs (Figure 3B,D)
the maximal orthogonal view showing the 3D composite image of the CTC. Z-stacks were created
per CTC, which were spatially rotated to capture signals within the nuclear space and to represent
the maximal orthogonal view. Deconvolution algorithms were used to further interrogate the images
(constrained iterative algorithm, Zeiss). Video imaging through the nuclear volume of the CTCs
showing the variation of signal within the planes is in the Supplementary Materials. Signals were
validated by an experienced cytogeneticist. No ALK-translocated CTCs were found in patients with
non-ALK-rearranged tumors.
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Figure 1. Of the 8 patients with ALK-translocated tumors, 5 had detectable CTCs (Patients # 1–5); 4/5
of the CTC-positive patients had ALK-rearranged CTCs, the percentage of which is shown in the grey.
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Figure 3. Examples of ALK-translocated CTCs imaged using 3D DNA FISH. (A,C) The gallery of
sequential z-stacks showing the additional signals found within the nuclear volume. (B,D) The maximal
orthogonal view showing the 3D composite image of the CTC. The 3′-ALK (red), 5′-ALK (green), and
DAPI (blue). Scale bar represents 10 µm. Video of imaging through the nuclear volume (Supplementary
Materials).
in patient survival and a reductio in toxicities in NSCLC patients. Whilst tumor
tissue biopsy is desirable to make these assessments in NSCLC patients, there are limitations on the
quantity and quality of tumor material available from a tissue biopsy. CTCs represent an alternative
source of tumor material, to assess the landscape of primary and metastatic tumor deposits in the
body by sampling blood. This represents a real-time, minimally invasive method of sampling which
can be performed serially over the course of treatment to understand the dynamic tumoral changes
in response to the selective pressures of treatment. A number of studies have reported on the
presence of ALK-translocated CTCs in blood taken from NSCLC patients [12,14,15,17,21–23] with
recent findings from Pailler et al., 2019, sequencing single CTCs that revealed the heterogeneity and
resistance mutations in ALK-rearranged patients. The study by Pailler et al., 2019, demonstrated that
various genes involved in the RTK-KRAS and TP53 pathways were found in patients with crizotinib
resistance [24]. Therefore, the ability to assess the mutational changes in real time and over the course
of therapy is of critical importance. The analysis of CTCs is gaining traction to determine molecular
alterations which would make the patients eligible for targeted therapies, often when tumor tissue
is a limiting factor to determine tumoral information [15,25]. Whilst the immediate application was
developed in NSCLC, this can be extended to other molecular alterations across a number of tumor
types [21].
Our study demonstrated that by spiral chip enrichment, CTC ALK rearrangements could be
detected routinely using DNA FISH, and that imaging CTCs in 3D presented the 3′ and 5′ signal
within the nuclear volume more readily compared to conventional 2D imaging for an assessment
of ALK translocations. Imaging using 3D DNA FISH offers visual and direct results where spatial
assessments of the nucleus can be made [20]. On occasions where the 3′ and 5′ signals were not clear,
rotation of the CTC about an axis would enable the interrogation of the signal. Imaging through the
nuclear volume presented a robust method to determine whether an ALK translocation was present
or whether the 3′ and 5′ signals were in close proximity/overlapping. The measurement of nuclear
distances and the number of nuclei can be time-consuming, however, the addition of image automation
may provide a more routine and robust process prior to clinical implementation. A similar approach
was recently described by Lim et al., 2018, using subtraction enrichment and immunostaining in situ
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hybridization (SE-FISH) [18]. A limitation of DNA FISH includes the harsh treatments required to
prepare the chromatin for the FISH probes, which can disrupt the nuclear structure. To overcome these,
strategies have been developed such as freeze–thaw permeabilization of cells and denaturation using
heat, prior to probe hybridization [20]. A limitation of enrichment with the spiral technology is that
CTCs that are of comparable size to WBCs or smaller are often not captured using this size-based CTC
capture methodology [26]. Whilst proof-of-principle, the authors envisage expanding this study to
a larger validation cohort of NSCLC patients (including patients with ALK/ROS-1 alterations) and
collecting follow-up samples to determine the changes in CTCs over the course of treatment.
Tumor tissue uses a threshold of 15% of ALK-translocated cells to diagnose a patient as
ALK-positive. Whilst our findings are preliminary, expansion of our study may enable the development
of a CTC threshold. A number of groups have attempted to develop such a threshold for NSCLC [12,27].
In the study by Pailler and colleagues, they demonstrated that four or more ALK-rearranged CTCs per
mL of blood gave a sensitivity and specificity of 100% when compared to tumor tissue. Moreover, no
or one ALK-rearranged CTC was found in ALK-negative patients [12]. In our study, we did not find
any ALK-translocated CTCs in the ALK-negative cohort of patients. This, in part, could be due to the
combination of spiral microfluidic chip enrichment, which reduces the number of contaminating white
blood cells by multiple log-fold [28–31], and the comprehensive assessment of putative CTCs using 3D
DNA FISH for ALK translocations. However, this would need to be tested in a larger cohort of patients
to determine an ALK cut-off for CTCs predictive of ALK rearrangements present in the primary tissue.
4. Materials and Methods
4.1. Patient Cohort
Ethics approval was obtained from the Metro South Health District Human Research Ethics
Committee in accordance with the National Health and Medical Research Councils guidelines
(HREC/11/QPAH/331) to collect samples from the Princess Alexandra Hospital. All methodologies were
performed in accordance with these ethical guidelines and regulations. This study has institutional
approval from the Queensland University of Technology human ethics committee (1100001420).
Following written informed consent, 10 mL of blood was collected from n = 20 NSCLC patients prior
to therapy.
4.2. ALK CDx Assay
The companion diagnostic test (VENTANA D5G3) was used to determine ALK protein in tumor
tissue samples (formalin-fixed, paraffin-embedded tissue) stained with the BenchMark XT automated
staining instrument.
4.3. CTC Enrichment
Blood samples were processed within 4 h of collection as previously described [29,30]. In brief,
whole bloods were collected in K2EDTA tubes (BD-Plymouth, Plymouth, UK) and underwent red
blood cell lysis (Astral Scientific, Taren Point, Australia) in a 1 part blood to 3 parts lysis buffer to reduce
the cellular component passing through the microfluidic chip. After RBC lysis, the blood sample was
centrifuged at 300× g for 15 min. The cellular pellet was resuspended in 1X PBS (Thermo Scientific,
Waltham, MA, USA) and passed through the spiral chip using a syringe pump (Chemyx, Stafford,
TX, USA). After two rounds of enrichment to reduce the background leukocyte contamination, the
final CTC output was collected and spun down at 300× g for 5 min (Shandon Cytospin, Thermofisher
Scientific).
4.4. CTC Immunophenotyping
The CTC output was transferred onto poly-l-lysine-coated glass slides (Sigma-Aldrich, St. Louis,
MO, USA) for phenotyping by immunocytochemistry. Cells were stained using the CellSearch®
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antibody cocktail which targets pan-Cytokeratin, CD45, and DAPI (Menarini-Silicon Biosystems,
Bologna, Italy). Slides were incubated with the staining reagents as previously described [14,15]. The
slides were coverslipped and imaged on the Zeiss Axio Z2 microscope (Carl Zeiss, Ontario, CA, USA).
Preliminary results were categorized into CTC-positive or CTC-negative events prior to performing
DNA FISH.
4.5. DNA Fluorescence In Situ Hybridization
The immunofluorescence signal was removed by incubating the slides at 50 ◦C in a stripping
buffer (2% SDS, 0.8% β-mercaptoethanol, 0.0625 M Tris-HCl, pH 6.8) for approximately 15 min with
agitation. The slides were then washed in 1X PBS three times for 5 min. The slides were then fixed in 4%
paraformaldehyde (Thermofisher Scientific, USA) and dehydrated via an ethanol series (70%, 85%, and
96%). Slides were treated with RNase (4 mg/mL) (Sigma, USA) and fluorescence in situ hybridization
(FISH) carried out using the Vysis LSI ALK break-apart probes (Abbott, USA), coverslipped and sealed
with rubber cement, placed in a humid chamber at 37 ◦C overnight (18–20 h), and counterstained
with DAPI as described by the manufacturer. To preserve the signal, prolong gold antifade medium
(Invitrogen, USA) was applied prior to coverslipping and imaging. Slides were imaged on the Zeiss
Axio Imager Z2 microscope. ALK-positive (ProbeChek 06N38-010) and ALK-negative (ProbeChek
06N38-005) control tissue slides were sourced from Abbott Molecular, USA.
4.6. 3D DNA FISH
Slides were imaged on the Zeiss Axio Z2 microscopy at 63X under oil immersion. FISH scanning
parameters (z stack, distance between z-stacks, and exposure times) were optimized for FISH signal
identification. A multiexposure protocol was developed for optimal capture of signal using a range of
between 5 and 25 stacks, and a distance of 0.1–0.5 µm between two successive stacks. Zen software
(Zeiss) was used to interrogate the 3D images of the CTCs. Signals were captured by experienced
users and the ALK status validated by an experienced molecular pathologist. In native ALK cells,
overlapping of the 3′ and 5′ signals produced a fusion signal, which was yellow. The characteristic
ALK translocation was observed when there was a split of the 3′ and 5′ signal of more than two signal
diameters. The number of ALK-rearranged nuclei per cytospot was enumerated and reported as a
percentage from the total number of CTCs identified.
5. Conclusions
In summary, we found that imaging CTCs for molecular alterations using 3D DNA FISH for ALK
translocations was a feasible method for analyzing CTCs in NSCLC patients. As part of a larger study,
we will focus on serial sampling of these patients to understand the changes in CTCs over the course
of therapy.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/9/6/1465/s1,
Video. ALK-translocated CTCs imaged through the nuclear volume to show the separation of ALK signal within
the multiple planes (imaged and analyzed on the Nikon Axio Z2 microscope (Carl Zeiss)).
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